Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
0.734
-0.006 (-0.80%)
At close: Jun 26, 2026, 4:00 PM EDT
0.774
+0.040 (5.45%)
After-hours: Jun 26, 2026, 7:29 PM EDT
Standard BioTools Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Standard BioTools stock has a target of 1.35, which predicts an increase of 83.87% from the current stock price of 0.73.
Analyst Consensus: Buy
* Price targets were last updated on May 6, 2026.
Analyst Ratings
The average analyst rating for Standard BioTools stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold Maintains $1.35 | Hold | Maintains | $1.35 | +83.87% | May 6, 2026 |
| KeyBanc | KeyBanc | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Feb 25, 2026 |
Financial Forecast
Revenue This Year
82.50M
from 85.33M
Decreased by -3.32%
Revenue Next Year
84.10M
from 82.50M
Increased by 1.94%
EPS This Year
0.03
from -0.14
EPS Next Year
-0.01
from 0.03
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 82.5M | 86.1M | |
| Avg | 82.5M | 84.1M | |
| Low | 82.5M | 82.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.3% | 4.4% | |
| Avg | -3.3% | 1.9% | |
| Low | -3.3% | -0.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.03 | -0.01 | |
| Avg | 0.03 | -0.01 | |
| Low | 0.03 | -0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.